Navigation Links
Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics
Date:7/22/2008

Latest awards under Therapeutics Development Initiative bring MJFF's current active industry collaborations to 23; next deadline January 20, 2009

NEW YORK, July 22 /PRNewswire-USNewswire/ -- As part of its mission to speed delivery of transformative treatments and a cure for Parkinson's disease, The Michael J. Fox Foundation for Parkinson's Research has awarded $2.7 million in total funding to six industry research teams. The awards were granted under MJFF's Therapeutics Development Initiative (TDI) program. Open exclusively to researchers at biotech and pharmaceutical companies, TDI is the cornerstone of the Foundation's venture philanthropy efforts to spark and expand industry investment in PD drug development. In an increasingly risk-averse research funding climate, TDI helps to push promising candidate therapeutics forward in industry pipelines by allowing the Foundation to share the risk of drug development.

"At MJFF, our job is to do whatever it takes to speed therapeutics development for Parkinson's disease," said Katie Hood, CEO of The Michael J. Fox Foundation. "Early on we realized the critical importance of forging financial and intellectual partnerships with industry as well as academic research teams. Our private philanthropy dollars -- raised largely from patients themselves -- have a critical role to play in 'de-risking' therapeutic targets for industry investment in order to keep the most promising ideas moving forward toward clinical testing and pharmacy shelves."

Funded projects focus on:

-- Developing a vaccine that could protect against toxicity of the PD-implicated protein alpha-synuclein (Ingeborg Muehldorfer, Ph.D., Rentschler Biotechnologie, Laupheim, Germany);

-- Improving delivery of the gold-standard Parkinson's treatment, levodopa, which could lessen debilitating side effects of the drug including dyskinesias, the uncontrollable movements that arise with long-term levodopa therapy (Verne Cowles, P
'/>"/>

SOURCE Michael J. Fox Foundation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
2. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
3. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
4. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
5. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
6. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
7. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
8. PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
9. Childrens Brain Tumor Foundations Tissue Bank Consortium May Solve Dire Problem in Pediatric Cancer Research
10. Canopus BioPharma Strengthens its CB1400 Platform Technology for Mucositis and Oncology Treatments Through License Agreement With Wisconsin Alumni Research Foundation
11. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... January 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ...
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... Calif. , April 23 PRO-DEX, INC. (Nasdaq: PDEX ) ... period ended March 31, 2010 on Thursday, April 29, 2010 ... , , ... Eastern Time ( 1:30 Pacific Time ) to discuss operating performance for ...
... VIENNA , April 23, 2010 ... progressed to phase II clinical testing.,It may therefore be possible ... 2012. Indeed the start of this efficacy study comes only ... The company,is active in several disease areas and is currently ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2010 Third Quarter Financial Results Conference Call and Webcast 2Pro-Dex, Inc. Announces Fiscal 2010 Third Quarter Financial Results Conference Call and Webcast 3AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 2AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 3AFFiRiS AG: Alzheimer's Vaccine AD02 Already in Clinical Phase II 4
(Date:4/17/2014)... who show signs of chronic inflammation in non-cancerous prostate ... having prostate cancer than those with no inflammation, according ... from the Johns Hopkins Kimmel Cancer Center. , The ... for men with so-called high-grade prostate cancer those ... indicating the presence of the most aggressive and rapidly ...
(Date:4/17/2014)... One of the most popular vaccine brands for ... doctors may be overlooking some cost factors when choosing ... more expensive option, according to a new study by ... to administer can be driven by numerous factors," says ... a professor of computer science and of mathematics at ...
(Date:4/17/2014)... San Diego School of Medicine report that older women, ... major loss are more likely to be compassionate toward ... published in this month,s issue of the International ... are associated with better health and well-being as we ... improve the outcomes of individuals whose deficits in compassion ...
(Date:4/17/2014)... Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently invited ... of Nature Reviews Microbiology , one of ... a world-renowned infectious disease specialist, and chair of ... Tennessee Health Science Center, analyzed the epidemiology and ... 1968 pandemics, as well as more recent 2009 ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... Cardiac Science (Nasdaq: CSCX ), ... rehabilitation, and informatics products, today announced that it ... Association (WBBA) 2009 Invest Northwest CEO and Investor ... in Seattle. Michael Matysik, senior vice president and ...
... Nausea and Vomiting (PONV)CORONA DEL MAR, Calif., March 11 ... patient,s oxygen status known on a beat-by-beat basis. Not ... say that all patients should have this monitor. No ... ASA Newsletter on their web site between 1983 and ...
... Interactive, Inc. was accepted as an affiliate member of ACA International ... as the American Collectors Association. , ... (Vocus) March ... Ave Ste 100, Plantation, FL 33324-3223, was accepted as an affiliate ...
... Corporation with a Scalable, Powerful System in Support of Patient Safety ... ... Francisco, CA (PRWEB) March 11, 2009 -- The Florida Patient Safety ... certified as a Patient Safety Organization (PSO), has chosen Quantros ...
... a toy drive at Build-A-Bear during annual team-building event , ... ... Cydcor , the leading provider of outsourced, face-to-face sales teams, hosted ... annual corporate kick-off meeting. , ,About 70 participating Cydcor ...
... BC Decker Inc, publisher of the acclaimed general surgical reference, ACS ... MD, FACS as the new Editor-in-Chief , ... Philadelphia, ... the acclaimed general surgical reference, ACS Surgery, is honored to announce ...
Cached Medicine News:Health News:Cardiac Science to Present at the Eighth Annual Invest Northwest Conference 2Health News:American Society of Anesthesiologists (ASA) - Myths About 'Never Ending Pursuit of Patient Safety and Satisfaction' Debunked 2Health News:Business Becomes Affiliate Member of International Trade Association 2Health News:The Nation's First Federally Certified Patient Safety Organization Chooses Quantros Patient Safety Organization Manager 2Health News:The Nation's First Federally Certified Patient Safety Organization Chooses Quantros Patient Safety Organization Manager 3Health News:The Nation's First Federally Certified Patient Safety Organization Chooses Quantros Patient Safety Organization Manager 4Health News:The Nation's First Federally Certified Patient Safety Organization Chooses Quantros Patient Safety Organization Manager 5Health News:Cydcor Builds Bears and Bonds in Special Charity Event Benefitting Childrens Hospital Los Angeles 2Health News:New Editor, New Vision for ACS Surgery 2Health News:New Editor, New Vision for ACS Surgery 3
... For the qualitative ... falciparum (P.f) antigen and an ... all four species of malaria:plasmodium ... Plasmodium ovale (P.o) and Plasmodium ...
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
... combines full 0.25 mm pb protection ... drape material that can be placed ... the clinician and the source of ... must be in very close proximity ...
... only insulin pen with a memory. HumaPen MEMOIR records ... doses (including priming doses). You can see exactly when ... MEMOIR, you simply "dial" your dose by turning the ... after initial set-up. If you dial too many units, ...
Medicine Products: